References | Journal | Year | |
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations Bing Sun, Norina Tang, Michael J. Peluso, Nikita S. Iyer, Leonel Torres, Joanna L. Donatelli, Sadie E. Munter, Christopher C. Nixon, Rachel L. Rutishauser, Isabel Rodriguez-Barraquer, Bryan Greenhouse, John D. Kelly, Jeffrey N. Martin, Steven G. Deeks, Timothy J. Henrich, and Lynn Pulliam | Cells | 2021 | View |
Altered maternal immune networks are associated with adverse child neurodevelopment: Impact of alcohol consumption during pregnancy Tamara S. Bodnar, Charlis Raineki, Wladimir Wertelecki, Lyubov Yevtushok, Larisa Plotka, Natalya Zymak-Zakutnya, Gordon Honerkamp-Smith, Alan Wells, Matthieu Rolland, Todd S. Woodward, Claire D. Coles, Julie A. Kable, Christina D. Chambers, Joanne Weinberg, and Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) | Brain, Behavior, and Immunity | 2019 | View |
Early and late effects of maternal experience on hippocampal neurogenesis, microglia, and the circulating cytokine milieu Rand S. Eid, Jessica A. Chaiton, Stephanie E. Lieblich, Tamara S. Bodnar, Joanne Weinberg, Liisa A.M. Galea | Neurobiology of Aging | 2019 | View |
CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease Jonathan D. Cherry , Thor D. Stein, Yorghos Tripodis, Victor E. Alvarez, Bertrand R. Huber, Rhoda Au, Patrick T. Kiernan, Daniel H. Daneshvar, Jesse Mez, Todd M. Solomon, Michael L. Alosco, Ann C. McKee | PLOS ONE | 2017 | View |
Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration. Toombs J, Foiani MS, Paterson RW, Heslegrave A, Wray S, Schott JM, Fox NC, Lunn MP, Blennow K, Zetterberg H. | J Alzheimers Dis. | 2017 | View |
Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. Lee EE, Hong S, Martin AS, Eyler LT, Jeste DV. | Am J Geriatr Psychiatry. | 2017 | View |
Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Höglund K, Kern S, Zettergren A, Börjesson-Hansson A, Zetterberg H, Skoog I, Blennow K. | Translational Psychiatry | 2017 | View |
Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Notter T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, Wang Y, Kassiou M, Vernon AC, Benke D, Pomper MG, Sawa A, Meyer U. | Mol Psychiatry. | 2017 | View |
Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic Phenotype. Whitehouse IJ, Brown D, Baybutt H, Diack AB, Kellett KA, Piccardo P, Manson JC, Hooper NM. | PLoS One. | 2016 | View |
Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Hong S, Lee EE, Martin AS, Soontornniyomkij B, Soontornniyomkij V, Achim CL, Reuter C, Irwin MR, Eyler LT, Jeste DV. | Schizophr Res. | 2016 | View |
Administrations of human adult ischemia-tolerant mesenchymal stem cells and factors reduce amyloid beta pathology in a mouse model of Alzheimer's disease. Harach T, Jammes F, Muller C, Duthilleul N, Cheatham V, Zufferey V, Cheatham D, Lukasheva YA, Lasser T, Bolmont T. | Neurobiol Aging. | 2016 | View |
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. Belichenko PV, Madani R, Rey-Bellet L, Pihlgren M, Becker A, Plassard A, Vuillermot S, Giriens V, Nosheny RL, Kleschevnikov AM, Valletta JS, Bengtsson SK, Linke GR, Maloney MT, Hickman DT, Reis P, Granet A, Mlaki D, Lopez-Deber MP, Do L, Singhal N, Masliah E, Pearn ML, Pfeifer A, Muhs A, Mobley WC. | PLoS One. | 2016 | View |
Brain Amyloid-β Plays an Initiating Role in the Pathophysiological Process of the PS1V97L-Tg Mouse Model of Alzheimer's Disease. Wang W, Lu L, Wu QQ, Jia JP. | J Alzheimers Dis. | 2016 | View |
Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease. Steen Jensen C, Portelius E, Siersma V, Høgh P, Wermuth L, Blennow K, Zetterberg H, Waldemar G, Gregers Hasselbalch S, Hviid Simonsen A. | Dement Geriatr Cogn Disord. | 2016 | View |
Conversion of Synthetic Aβ to In Vivo Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model. Novotny R, Langer F, Mahler J, Skodras A, Vlachos A, Wegenast-Braun BM, Kaeser SA, Neher JJ, Eisele YS, Pietrowski MJ, Nilsson KP, Deller T, Staufenbiel M, Heimrich B, Jucker M. | J Neurosci. | 2016 | View |
CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, Bittner T, Korecka M, Jenkins RG, Vanderstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers I, Schimmel H, Zetterberg H, Blennow K; IFCC Working Group on Standardization of CSF proteins (WG-CSF). | Clin Chim Acta. | 2016 | View |
Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? Föcking M, Dicker P, Lopez LM, et al. | BMC Psychiatry. | 2016 | View |
Gray matter regions statistically mediating the cross-sectional association of eotaxin and set-shifting among older adults with major depressive disorder. Smagula SF, Karim HT, Lenze EJ, Butters MA, Wu GF, Mulsant BH, Reynolds CF 3rd, Aizenstein HJ. | Int J Geriatr Psychiatry. | 2016 | View |
Immunological biomarkers associated with brain structure and executive function in late-life depression: exploratory pilot study. Smagula SF, Lotrich FE, Aizenstein HJ, Diniz BS, Krystek J, Wu GF, Mulsant BH, Butters MA, Reynolds CF 3rd, Lenze EJ. | Int J Geriatr Psychiatry. | 2016 | View |
In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, Kim PK, Ford CN, Higgs C, Hayes LN, Schretlen DJ, Dannals RF, Kassiou M, Sawa A, Pomper MG. | Transl Psychiatry. | 2016 | View |
Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Chen A, Oakley AE, Monteiro M, Tuomela K, Allan LM, Mukaetova-Ladinska EB, O'Brien JT, Kalaria RN. | Neurobiol Aging. | 2016 | View |
Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Olmos-Alonso A, Schetters ST, Sri S, Askew K, Mancuso R, Vargas-Caballero M, Holscher C, Perry VH, Gomez-Nicola D. | Brain. 2016 Mar;139(Pt 3):891-907. | 2016 | View |
Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Schelle J, Häsler L, Göpfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA. | Alzheimers Dement. | 2016 | View |
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, Cummins GA, Duncan GW, Khoo TK, Burn DJ, Barker RA; ICICLE-PD study group. | Mov Disord. | 2016 | View |
Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-β peptides in human cerebrospinal fluid and application to a clinical cohort. Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, Muck S, Scherbaum N, Wiltfang J. | J Alzheimers Dis. | 2016 | View |